Akero - Wutah pendapatan triwulanan AKRO

Akero Therapeutics (AKRO) - logo korporat

Akero Therapeutics (AKRO) lacks stable cash flows, as it relies exclusively on external capital until its products reach the market. The company's quarterly revenue growth, as seen on the GURU.Markets chart, shows that 0.00 is hitting a new level, while the business risks a collapse in capitalization due to potential failures in liver drug trials. However, the diversification of several metabolic pathology research programs mitigates the overall risks.

AKRO Tingkat wutah dodolan sajrone kuartal Akero Therapeutics Inc (04.07.2022 - 20.12.2025)

Ringkesan rincian data analitis Akero Therapeutics, Inc. (AKRO)

- kuotasi saiki lan rata-rata prakiraan nilai:
- indikator dhuwit lan arus kas:
Analisis kabeh metrik perusahaan:Akero Therapeutics, Inc. (AKRO)
Produk sing diprodhuksi Akero

A fundamental risk assessment requires an analysis of actual sales dynamics, where quarter-over-quarter revenue growth rates allow for the filtering of inflationary noise and the identification of fading commercial momentum. For Akero Therapeutics (AKRO), this metric reflects market demand for its AI solutions and robotic bioanalysis systems, demonstrating the efficiency of clinical test automation through the percentage change in revenue between consecutive periods.

Pesaing utama

ASND - Wutah pendapatan kuartal marang kuartal|MDGL: Wutah pendapatan kuartal marang kuartal|CORT: Wutah pendapatan triwulanan|RYTM - Tingkat wutah dodolan sajrone kuartal|Wutah pendapatan kuartal marang kuartal Metsera Therapeutics|MoonLake Corp (MLTX) - Tingkat wutah dodolan sajrone kuartal|Wutah pendapatan kuartal marang kuartal crinetics.com (CRNX)|Wutah dodolan triwulanan newamsterdampharma.com NAMS|Wutah pendapatan kuartal marang kuartal Soleno Therapeutics Inc SLNO|Wutah pendapatan triwulanan Amicus Therapeutics Inc FOLD|89bio Corp - Wutah pendapatan triwulanan|Owah-owahan pendapatan dibandhingake kuartal kepungkur Agios Pharmaceuticals Inc (AGIO)|Structure Therapeutics (GPCR) - Wutah pendapatan kuartal marang kuartal|Wutah dodolan triwulanan MiMedx Group, Inc.|Wutah pendapatan kuartal marang kuartal Rezolute Bio|Lexicon Pharmaceuticals, Inc. (LXRX) - Tingkat wutah dodolan sajrone kuartal|Wutah pendapatan triwulanan MBX|Wutah dodolan triwulanan Altimmune, Inc. ALT|Wutah pendapatan triwulanan AARD (Aardvark Pharma)|Sagimet Biosciences Inc. (SGMT) - Tingkat wutah pendapatan sajrone kuartal|BIOA: Wutah dodolan triwulanan|Tambahing pendapatan triwulanan BMEA (Biomea Fusion)|QNCX (quincetx.com) - Wutah dodolan triwulanan|Fractyl - Tambahing pendapatan triwulanan|VTVT (vTv Therapeutics Inc) - Wutah pendapatan triwulanan|Agape ATP - Dinamika pendapatan kuartal marang kuartal|Wutah dodolan triwulanan PLUR (Pluri Inc)|Tingkat wutah dodolan sajrone kuartal Synlogic Inc.|Wutah pendapatan kuartal marang kuartal Lipocine Inc. LPCN|Matinas BioPharma (MTNB) - Tingkat wutah pendapatan sajrone kuartal|Spruce Biosciences Inc. - Wutah pendapatan triwulanan|Tingkat wutah dodolan sajrone kuartal Galecto, Inc. GLTO|Carmell Therapeutics (CTCX) - Wutah pendapatan kuartal marang kuartal|Lumos Pharma - Tambahing pendapatan triwulanan|ONVO (Organovo Corp) - Wutah pendapatan triwulanan|Radius Pharmaceuticals (RDUS) - Tingkat wutah dodolan sajrone kuartal